DNLI Q3 2021 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-43.7% YoY

Gross Profit

$5M100.0% margin

Operating Income

-$86M-1619.5% margin

Net Income

-$85M-1600.5% margin

EPS (Diluted)

$-0.69

QoQ Revenue Growth

-77.0%

Cash Flow

Operating Cash Flow

-$41M

Free Cash Flow

-$43M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$438M

Stockholders' Equity

$1.0B

Cash & Equivalents

$395M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$9M	-43.7%
Gross Profit	$5M	$9M	-43.7%
Operating Income	-$86M	-$60M	-42.4%
Net Income	-$85M	-$58M	-45.3%